Viking Therapeutics (VKTX) Competitors $26.62 +0.58 (+2.23%) Closing price 04:00 PM EasternExtended Trading$26.46 -0.17 (-0.62%) As of 06:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock VKTX vs. MDGL, LLY, GMAB, VTRS, ASND, RDY, MRNA, QGEN, BBIO, and VRNAShould you be buying Viking Therapeutics stock or one of its competitors? The main competitors of Viking Therapeutics include Madrigal Pharmaceuticals (MDGL), Eli Lilly and Company (LLY), Genmab A/S (GMAB), Viatris (VTRS), Ascendis Pharma A/S (ASND), Dr. Reddy's Laboratories (RDY), Moderna (MRNA), Qiagen (QGEN), BridgeBio Pharma (BBIO), and Verona Pharma PLC American Depositary Share (VRNA). These companies are all part of the "medical" sector. Viking Therapeutics vs. Its Competitors Madrigal Pharmaceuticals Eli Lilly and Company Genmab A/S Viatris Ascendis Pharma A/S Dr. Reddy's Laboratories Moderna Qiagen BridgeBio Pharma Verona Pharma PLC American Depositary Share Viking Therapeutics (NASDAQ:VKTX) and Madrigal Pharmaceuticals (NASDAQ:MDGL) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, analyst recommendations, media sentiment, risk, institutional ownership and dividends. Do institutionals & insiders believe in VKTX or MDGL? 76.0% of Viking Therapeutics shares are held by institutional investors. Comparatively, 98.5% of Madrigal Pharmaceuticals shares are held by institutional investors. 4.1% of Viking Therapeutics shares are held by company insiders. Comparatively, 21.5% of Madrigal Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Is VKTX or MDGL more profitable? Viking Therapeutics has a net margin of 0.00% compared to Madrigal Pharmaceuticals' net margin of -54.68%. Viking Therapeutics' return on equity of -19.98% beat Madrigal Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Viking TherapeuticsN/A -19.98% -19.38% Madrigal Pharmaceuticals -54.68%-38.38%-27.32% Which has more risk & volatility, VKTX or MDGL? Viking Therapeutics has a beta of 0.67, indicating that its share price is 33% less volatile than the S&P 500. Comparatively, Madrigal Pharmaceuticals has a beta of -1.02, indicating that its share price is 202% less volatile than the S&P 500. Which has higher valuation and earnings, VKTX or MDGL? Viking Therapeutics has higher earnings, but lower revenue than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Viking Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioViking TherapeuticsN/AN/A-$109.96M-$1.53-17.40Madrigal Pharmaceuticals$180.13M52.39-$465.89M-$12.85-33.08 Does the media favor VKTX or MDGL? In the previous week, Madrigal Pharmaceuticals had 9 more articles in the media than Viking Therapeutics. MarketBeat recorded 29 mentions for Madrigal Pharmaceuticals and 20 mentions for Viking Therapeutics. Madrigal Pharmaceuticals' average media sentiment score of 0.95 beat Viking Therapeutics' score of 0.11 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viking Therapeutics 7 Very Positive mention(s) 4 Positive mention(s) 6 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Madrigal Pharmaceuticals 13 Very Positive mention(s) 3 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend VKTX or MDGL? Viking Therapeutics currently has a consensus target price of $86.92, indicating a potential upside of 226.53%. Madrigal Pharmaceuticals has a consensus target price of $459.25, indicating a potential upside of 8.04%. Given Viking Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Viking Therapeutics is more favorable than Madrigal Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Viking Therapeutics 0 Sell rating(s) 2 Hold rating(s) 10 Buy rating(s) 2 Strong Buy rating(s) 3.00Madrigal Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.90 SummaryViking Therapeutics beats Madrigal Pharmaceuticals on 11 of the 16 factors compared between the two stocks. Get Viking Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VKTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VKTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VKTX vs. The Competition Export to ExcelMetricViking TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.99B$3.09B$5.74B$9.78BDividend YieldN/A2.26%4.40%4.04%P/E Ratio-17.4021.2230.8326.39Price / SalesN/A206.90382.9086.63Price / CashN/A44.2437.7259.11Price / Book3.778.0710.106.62Net Income-$109.96M-$54.08M$3.26B$265.42M7 Day Performance3.62%3.94%3.90%3.58%1 Month Performance-22.66%3.02%3.73%0.46%1 Year Performance-56.65%6.84%37.68%19.41% Viking Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VKTXViking Therapeutics3.9581 of 5 stars$26.62+2.2%$86.92+226.5%-60.3%$2.99BN/A-17.4020MDGLMadrigal Pharmaceuticals3.8643 of 5 stars$391.43+5.8%$439.71+12.3%+66.1%$8.69B$180.13M-30.4690Analyst ForecastHigh Trading VolumeLLYEli Lilly and Company4.9993 of 5 stars$698.89-0.3%$950.17+36.0%-22.7%$661.47B$53.26B45.6847,000Trending NewsAnalyst UpgradeGMABGenmab A/S3.7004 of 5 stars$23.43+0.5%$37.60+60.5%-10.3%$15.03B$3.12B11.772,682News CoverageVTRSViatris1.9188 of 5 stars$10.63+0.2%$10.40-2.2%-11.4%$12.39B$14.74B-3.6732,000ASNDAscendis Pharma A/S3.4205 of 5 stars$194.59-1.9%$242.93+24.8%+42.0%$11.91B$393.54M-37.711,017Positive NewsRDYDr. Reddy's Laboratories3.071 of 5 stars$14.26+0.2%$16.95+18.9%-13.7%$11.90B$3.81B21.6027,811News CoveragePositive NewsMRNAModerna4.4987 of 5 stars$28.08+0.2%$43.59+55.3%-69.7%$10.92B$3.24B-3.735,800QGENQiagen4.0132 of 5 stars$48.66-1.4%$49.69+2.1%+11.3%$10.82B$1.98B28.755,765News CoverageBBIOBridgeBio Pharma4.293 of 5 stars$49.02-4.5%$61.35+25.2%+88.7%$9.37B$221.90M-11.99400VRNAVerona Pharma PLC American Depositary Share2.4814 of 5 stars$105.79+0.5%$109.00+3.0%+295.9%$9.01B$42.28M-106.8630Positive News Related Companies and Tools Related Companies Madrigal Pharmaceuticals Competitors Eli Lilly and Company Competitors Genmab A/S Competitors Viatris Competitors Ascendis Pharma A/S Competitors Dr. Reddy's Laboratories Competitors Moderna Competitors Qiagen Competitors BridgeBio Pharma Competitors Verona Pharma PLC American Depositary Share Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VKTX) was last updated on 8/27/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Viking Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Viking Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access